NovaBay Pharmaceuticals I... (NBY)
Company Description
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally.
It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands.
The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand.
It sells its products through retailers, digital beauty channels, and distributors, as well as online.
The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007.
NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Country | United States |
IPO Date | Oct 26, 2007 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 24 |
CEO | Justin M. Hall Esq. |
Contact Details
Address: 2000 Powell Street EmeryVille, California United States | |
Website | https://novabay.com |
Stock Details
Ticker Symbol | NBY |
Exchange | AMEX |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001389545 |
CUSIP Number | 66987P201 |
ISIN Number | US66987P3001 |
Employer ID | 68-0454536 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Justin M. Hall Esq. | President, Chief Executive Officer, General Counsel, Chief Compliance Officer, Corporate Secretary & Director |
Tommy Law | Controller, Interim Chief Financial Officer & Treasurer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 02, 2025 | 10-K | Annual Report |
Apr 01, 2025 | NT 10-K | Filing |
Mar 19, 2025 | DEF 14A | Filing |
Mar 11, 2025 | 8-K | Current Report |
Mar 07, 2025 | DEFA14A | Filing |
Mar 07, 2025 | 8-K | Current Report |
Feb 18, 2025 | PRE 14A | Filing |
Feb 06, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 04, 2025 | DEFA14A | Filing |
Feb 04, 2025 | 8-K | Current Report |